The active ingredient in Ozempic was associated with a reduced risk of Alzheimer's disease-related dementia among diabetes patients.

A new review of clinical trial data finds evidence that GLP-1 drugs can meaningfully reduce dementia risk in people with type 2 diabetes.

The exact numbers depended on the type of medication patients took, but the risk of developing Alzheimer’s was up to 70 ...

They were designed to treat diabetes, then prescribed for weight loss, and now—as researchers are finding—they might hold the secret to staving off Alzheimer’s, too.

Obesity and diabetes drugs, particularly semaglutides like Wegovy and Ozempic, may reduce a person’s risk of dementia, a new study suggests.

“According to the latest figures released by the NHS, dementia diagnosis is at a record high in England. “This is great news for residents, as increased awareness results in increased ...

Does Ozempic also hold the secret to a cure for depression and dementia? As Wes Streeting suggests new weight-loss jabs could be given to unemployed people to help them get back into work, doctors ...

GLP-1 medications offer promising benefits for obesity and diabetes patients, with studies showing reduced heart attack risk and potential applications for addiction treatment.

Ozempic and similar novel diabetes treatments may lower the risk of Alzheimer's disease and related dementias. This is the conclusion of a pair of studies by research teams from the U.S. and ...

Semaglutide — the active ingredient in type 2 diabetes and weight-loss glucagon-like peptide-1 agonist ( GLP-1) medications Ozempic and Wegovy — may help lower dementia risk, a new study finds.